 |
Quick Links |
| Information by Disease |
|
|
|
| Cancer News |
|
|
|
| Conference Coverage |
|
|
|
| AZN | $44.82 | -0.37 (-0.82%)
| | NVS | $53.13 | -0.16 (-0.3%)
| | SNY | $37.67 | -0.01 (-0.03%)
| | GSK | $41.53 | 0.06 (0.14%)
|
|
|
|
Renal Cancer - General
|
|
Excess Body Weight Linked with More Than 100,000 New Cancer Diagnoses Each Year in U.S. (11/12/2009)
According to estimates from the American Institute for Cancer Research (AICR), excess body weight may be responsible for more than 100,000 new cancer diagnoses each year in the United States.
Low-dose Interferon-alfa Does Not Improve Outcomes of Patients with Renal Cell Carcinoma Receiving Nexavar® (11/4/2009)
Researchers from the M. D. Anderson Cancer Center have reported that the addition of low-dose interferon-alfa (IFN) to Nexavar® (sorafenib) did not improve survivals of patients with advanced renal cell carcinoma (RCC). The details of this study were published early online in Cancer on October 27. 2009.
Nexavar® May Reduce Brain Metastases in Patients with Metastatic Renal Cell Carcinoma (10/28/2009)
Researchers from France and Poland have reported that Nexavar® (sorafenib) may reduce the incidence of brain metastases in patients with metastatic renal cell carcinoma (RCC). The details of this study appeared early online on October 22, 2009 in the Annals of Oncology.
Oral Targeted Agent Recentin™ Active in Renal Cell Carcinoma (9/25/2009)
Researchers involved in an international randomized Phase II clinical trial have reported that Recentin™ (cediranib), a potent inhibitor of vascular endothelial growth factor (VEGF) tyrosine kinases, is active for the treatment of patients with advanced renal cell carcinoma (RCC). The details of this study were presented as a late-breaking abstract at the Joint ECCO 15 – 34th ESMO Multidisciplinary Congress in Berlin, September 20-24, 2009.
Oral Tyrosine Multi-kinase Inhibitor, Pazopanib, Active in Advanced Renal Cell Carcinoma (9/24/2009)
Researchers from Europe have reported that pazopanib is an active new tyrosine kinase inhibitor for treating renal cell carcinoma. The details of this study were presented at the Joint ECCO 15 – 34th ESMO Multidisciplinary Congress in Berlin, September 20-24, 2009.
Robot-assisted Partial Nephrectomy Safe and Effective for Renal Tumors (9/22/2009)
Researchers from Washington University, Henry Ford Hospital, and NYU Langone Medical Center have reported that robot-assisted partial nephrectomy (RAPN) is a safe and effective alternative to laparoscopic partial nephrectomy (LPN) for renal tumors. The details of this study appeared in the September 2009 issue of the Journal of Urology.
Laparoscopic Radical Nephrectomy for Renal Cell Carcinoma Equivalent to Open Surgery (9/22/2009)
Researchers from the University of Southern California have reported that “Long-term oncological outcomes after laparoscopic radical nephrectomy (LRN) for renal cell carcinoma are excellent and comparable to those of open surgery.” The details of this study appeared in the Journal of Urology early online on September 14, 2009.
Broad Range of Patients with Renal Cell Carcinoma Benefit from Sutent® (9/14/2009)
Researchers from the UK have reported that Sutent® (sunitinib) is safe and effective for a broad population of patients with metastatic renal cell carcinoma. The results of this study were published in the August, 2009 issue of Lancet Oncology.
High Time Costs for Informal Care Givers of Cancer Patients (9/10/2009)
Researchers from the National Cancer Institute (NCI) have reported that the time spent by informal caregivers is significant and an important component in the overall burden of cancer care. The details of this study appeared in the September 4, 2009 issue of Cancer.
Axitinib Has Activity in Nexavar®-refractory Metastatic Renal Cell Carcinoma (9/2/2009)
Results of a U.S. multicenter trial have shown that axitinib has significant activity for the treatment of patients with Nexavar® (sorafenib)-refractory metastatic renal cell carcinoma. The details of this study appeared in an early online publication in the Journal of Clinical Oncology on August 3, 2009.
Afinitor® Confirmed Effective for Clear Cell Renal Cell Cancer (5/14/2009)
Researchers from the University of Texas Medical School have reported that the oral mTOR inhibitor RAD Afinitor® (everolimus) is active for the treatment of patients with clear renal cell cancer (RCC). The details of this study appeared in an early online publication on March 20, 2009 in Cancer.
Nexavar® Is Better Tolerated than Interferon in Patients with Metastatic Renal Cell Carcinoma (3/27/2009)
Researchers from France have reported that patients with untreated renal cell cancer (RCC) have equivalent progression-free survivals (PFS) following treatment with either Nexavar® (sorafenib) or interferon alfa-2a (IFNa2b); patients receiving Nexavar, however, experienced greater rates of tumor shrinkage and reported a better quality of life (QOL) than with interferon. The results of this study were published in the March 10, 2009 issue of the Journal of Clinical Oncology.
Type of Diet Does Not Increase Risk of Renal Cell Cancer (1/26/2009)
Researchers involved in an international study have reported that intake of fat, red meat, processed meat, poultry, or seafood is not associated with risk of renal cell cancer. The details of this study appeared in the December 3, 2008 issue of the Journal of the National Cancer Institute.
Cardiac Toxicity from Sutent® and Nexavar® During Treatment of Renal Cell Carcinoma Described (11/13/2008)
Researchers from the Medical University Vienna have reported that Sutent® (sunitinib) and Nexavar® (sorafenib) cause cardiac damage, but this does not interfere with survival. The results of this study were published in the November 10, 2008 issue of the Journal of Clinical Oncology.
Sutent® Provides Superior Quality of Life Compared with Interferon in Kidney Cancer (8/14/2008)
The targeted agent Sutent® (sunitinib) provides superior quality of life compared with interferon alfa for patients with advanced renal cell carcinoma (RCC). These results were recently published in the August 1, 208 issue of Journal of Clinical Oncology.
Adjuvant Chemotherapy Does Not Adversely Affect Quality of Life of Elderly Patients with Colorectal Cancer (8/11/2008)
Researchers from France have reported that patients 75 years of age or older with Stage III colon or rectal cancer receiving adjuvant chemotherapy or radiotherapy did not have negative effects on quality-of-life parameters compared with patients not receiving adjuvant therapy. The details of this study appeared in the August 15, 2008 issue of Cancer.
Everolimus Improves Progression-free Survival in Renal Cell Cancer (8/1/2008)
Researchers affiliated with an international randomized Phase III trial have reported that everolimus (RAD001) significantly prolongs progression-free survival among patients with advanced renal cell cancer (RCC) who have progressed following prior therapies. These results were published in an early online publication in The Lancet on July 23, 2008.
Risk Factors for Sutent® Toxicity in Renal Cell Cancer Defined (7/23/2008)
Researchers from the Netherlands have reported that severe toxicity following treatment of advanced renal cell carcinoma (RCC) with Sutent® (sunitinib) is related to low body surface, high age, and female gender. The details of this study appeared in the July 15, 2008 issue of the British Journal of Cancer.
Thalomid® and Revlimid® Active as Primary Treatment for Metastatic Renal Cell Carcinoma (7/1/2008)
Researchers from Methodist Hospital in Houston, Texas, have reported that both Revlimid® (lenalidomide) and Thalomid® (thalidomide) have significant activity in newly diagnosed patients with metastatic renal cell carcinoma (MRCC). The details of these two studies were published in the June 2008 issue of the American Journal of Clinical Oncology.
Study Confirms Efficacy of Sutent® for Initial Treatment of Metastatic Renal Cell Cancer (6/4/2008)
According to updated results from a Phase III clinical trial, initial treatment of metastatic renal cell cancer (RCC) with Sutent® (sunitinib) results in significantly better response rates and progression-free survival than treatment with interferon alfa. These results were presented at the 2008 annual meeting of the American Society of Clinical Oncology (ASCO).
Conventional Chemotherapy Outperforms Xeloda® in Older Breast Cancer Patients (6/4/2008)
Among women aged 65 or older with operable breast cancer, risk of recurrence and risk of death were higher among those treated with Xeloda® (capecitabine) monotherapy than among those treated with AC or CMF chemotherapy. These were the results of the CALGB/CTSU 49907 trial, presented at the 2008 annual meeting of the American Society of Clinical Oncology (ASCO).
Avastin® and Interferon Superior to Interferon Alone for Metastatic Renal Cell Carcinoma (5/15/2008)
Researchers affiliated with CALGB 90206 have reported that the addition of Avastin® (bevacizumab) to interferon improves overall and progression-free survival in patients with metastatic renal cell carcinoma. The details of this study were presented at the 2008 Genitourinary Cancers Symposium in San Francisco in February.
Oncophage® Vaccine May Have Activity in Renal Cell Carcinoma (4/8/2008)
Researchers from MD Anderson Cancer Center have reported that Oncophage® (vitespin, HSPPC-95) given with Proleukin® (interleukin-2) has activity in a minority of patients with metastatic renal cell carcinoma. The details of this study appeared in an early online publication in the British Journal of Cancer on March 25, 2008.
Alcohol Consumption Lowers Risk of Renal Cell Carcinoma (3/10/2008)
Researchers from Italy have reported an inverse relationship between alcohol consumption and the incidence of renal cell carcinoma (RCC). The details of this study appeared in an advanced publication in the Annals of Oncology on January 10, 2008.
High BMI Associated with Increased Risk of Cancer (2/21/2008)
Researchers from the UK have reported that persons with an increased body mass index (BMI) have a higher incidence of several cancers. The details of this study were published in the February, 2008, issue of Lancet Oncology.
Avastin® and Interferon Superior to Interferon Alone for Renal Cell Carcinoma (1/24/2008)
Researchers affiliated with a multicenter international trial have reported that the addition of Avastin (bevacizumab) to interferon improves progression-free survival of patients with metastatic renal cell carcinoma compared to interferon alone the details of this study were published in the December 22, 2007 issue of The Lancet.
Less Extensive Surgery May Benefit Younger Patients with Small Renal Tumors (1/21/2008)
Researchers from the Mayo Clinic have reported that radical nephrectomy in patients under the age of 65 with small, localized renal tumors, may result in worse overall survival than partial nephrectomy. These results were published in the February, 2008 issue of The Journal of Urology.
Nexavar® plus Interferon Effective in Metastatic Renal Cell Cancer (11/28/2007)
Researchers from Duke University and the University of North Carolina along with researchers affiliated with the National Cancer Institute have reported that Nexavar® (sorafenib) plus interferon alfa-2b (INF- α2b) appears to have substantial anticancer activity in the treatment of advanced renal cell cancer (RCC). The details of this study were published in the August 1, 2007 issue of the Journal of Clinical Oncology.
Increasing Body Mass Associated with Increasing Cancer Incidence and Mortality (11/19/2007)
Researchers affiliated with the UK Million Women Study have reported that increasing body mass index (BMI) is associated with an increased risk of 10 specific types of cancer out of 17 evaluated. The details of this study appeared in an early on-line publication on November 6, 2007 in the British Medical Journal.
Axitinib Provides Activity in Kidney Cancer (10/29/2007)
Researchers involved in a multicenter international trial have reported that oral axitinib (AG-013736), a potent inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2 and 3, has significant activity in cytokine refractory renal cell carcinoma (RCC). The details of this study appeared in an early on-line publication in Lancet Oncology, on October 23, 2007.
Siblings of Kidney Cancer Patients at Increased Risk for the Disease (7/16/2007)
European researchers have reported that a family history of kidney cancer increases risk of developing the disease, particularly among individuals who have a sibling diagnosed with kidney cancer. The details of this study appeared in the June, 2007 issue of Cancer Epidemiology, Biomarkers and Prevention.
Avastin® Improves Progression-Free Survival in Metastatic Renal Cell Cancer (6/20/2007)
Researchers affiliated with the international study, AVOREN, have reported that the addition of Avastin® (bevacizumab) to interferon improves progression-free survival when used as initial therapy among patients with metastatic renal cell carcinoma (mRCC). The details of this randomized trial were presented at a plenary session of the 2007 annual meeting of the American Society of Clinical Oncology (ASCO) in June.
Torisel™ Effective for Metastatic Renal Cell Carcinoma (6/7/2007)
An international randomized study has demonstrated superiority of Torisel (temsirolimus) over interferon alfa (INF-a) for the treatment of advanced renal cell carcinoma (RCC). The details of this study appeared in the May 31, 2007 issue of the New England Journal of Medicine.
Nexavar® Improves Progression-Free Survival in Advanced Kidney Cancer (1/22/2007)
Researchers affiliated with the TARGET Study Group reported that Nexavar (sorafenib) improves progression-free survival among patients with kidney cancer who have stopped responding to prior therapies when compared to placebo.
Sutent® Improves Progression-Free Survival Over Interferon in Kidney Cancer (1/18/2007)
A multicenter randomized trial has shown Sutent (sunitinib malate) improves responses and progression-free survival over interferon for the treatment of metastatic kidney cancer. The details of this study were published in the January 11, 2006, issue of the New England Journal of Medicine.
Role of Nexavar® for the Treatment of Renal Cell Cancer Summarized (12/4/2006)
Dr. Ronald Butowski from the Cleveland Clinic summarized the current data on treatment of refractory clear cell renal cell carcinoma with Nexavar (sorafenib) at the recent Chemotherapy Foundation Symposium XXIV in New York.
Revlimid® Has Activity in Metastatic Renal Cell Carcinoma (11/20/2006)
Researchers from the Cleveland Clinic have reported that Revlimid® (lenalidomide) has activity in patients with metastatic renal cell carcinoma (MRCC) who have not received prior therapy or failed only one previous therapy.
Eating Fatty Fish Associated with Decreased Incidence of Renal Cell Carcinoma in Women (9/21/2006)
Researchers in Sweden have reported that consumption of fatty fish may reduce the risk of developing renal cell carcinoma in women.
Lapatinib Superior to Hormonal Therapy in Patients with Renal Cell Carcinoma Failing Initial Therapy (7/6/2006)
Researchers have reported that lapatinib extends overall survival compared with hormonal therapy in patients with advanced renal-cell carcinoma that over-express epidermal growth factor receptor (EGFR). The details of this large randomized trial were presented at the June 2006 meeting of the American Society of Clinical Oncology in Atlanta, Georgia.
Multicenter Trial Confirms Effectiveness of Sutent® for Treatment of Metastatic Renal Cell Carcinoma (6/23/2006)
Researchers involved in a Phase II multicenter clinical trial have confirmed a response rate of 34% in patients with cytokine refractory metastatic renal cell carcinoma (RCC) treated with Sutent (SU 11248, sunitinib malate).
Nexavar® Improves Patient Outcomes Without Hurting Quality of Life (6/15/2006)
Treatment of advanced renal cell carcinoma with the targeted therapy Nexavar® (sorafenib) improves certain symptoms and does not adversely affect quality of life. These results were presented at the 2006 annual meeting of the American Society of Clinical Oncology (ASCO).
Phase III Trials Demonstrate Improved Outcomes for Metastatic Renal Cell Carcinoma After First-Line Therapy with Sutent or Temsirolimus (6/12/2006)
According to the results of two phase III clinical trials presented at the 2006 annual meeting of the American Society of Clinical Oncology (ASCO), first-line therapy with Sutent (sunitinib malate) significantly improves progression-free survival among patients with metastatic renal cell carcinoma (RCC), and first-line therapy with temsirolimus improves overall and progression-free survival among patients with poor-prognosis metastatic RCC.
Nexavar® Plus Best Supportive Care is Cost-Effective in Advanced Renal Cell Carcinoma (6/9/2006)
According to results presented at the 42nd annual meeting of the American Society of Clinical Oncology, the combination of Nexavar® (sorafenib) and best supportive care appears to be cost effective in the management of advanced renal cell carcinoma (RCC).
Updated Results from Phase III Trial of Nexavar® in Advanced Renal Cell Carcinoma (6/8/2006)
Updated results from the phase III Treatment Approaches in Renal cancer Global Evaluation Trial (TARGETs) suggest that treatment of advanced renal cell carcinoma (RCC) with the targeted therapy Nexavar® (sorafenib) improves survival even after extensive crossover from the placebo group; the level of statistical significance required for early cessation of the study, however, was not reached.
Nexavar® Plus Interferon-Alpha 2b Produces Promising Results in Metastatic Renal Cell Cancer (6/5/2006)
According to preliminary results from a phase II clinical trial presented at the 2006 meeting of the American Society of Clinical Oncology, first- or second-line treatment of metastatic renal cell cancer (RCC) with the combination of Nexavar® (sorafenib) and interferon-alpha 2b (IFN-α2b) produces promising response rates and is well tolerated.
Multicenter Trial Confirms That Nexavar® Has Significant Activity in Metastatic Renal Cell Carcinoma (5/15/2006)
The results of a phase II multicenter trial randomized discontinuation trial confirm that Nexavar (sorafenib), a multikinase inhibitor, has significant activity in patients with metastatic renal cell carcinoma.
Sutent® Approved by FDA for Treatment of Renal Cell Carcinoma and Gastrointestinal Stromal Tumor (4/4/2006)
In January 2006 the U.S. Food and Drug Administration (FDA) approved the use of Sutent (SU 11248, sunitinib malate) for the treatment of gastrointestinal stromal tumors (GIST) that had progressed after Gleevec® (imatinib) and for advanced renal cell carcinoma (RCC).
Thalomid® and IL-2 Effective for Metastatic Renal Cell Carcinoma (3/20/2006)
Researchers from the Methodist Hospital in Houston, Texas, have reported that treatment of metastatic renal cell carcinoma (MRCC) with interleukin-2 (IL-2) and Thalomid (thalidomide) results in a 52% disease control rate.
Multi-Targeted Inhibitor, SU11248, Active in Renal Cell Carcinoma (12/12/2005)
A multi-center trial has found that sunitinib malate (SU11248), an inhibitor of vascular endothelial growth factor (VEGF) receptor and platelet derived growth factor receptor (PDGF) has significant anti-tumor activity in patients with renal cell carcinoma (RCC).
Sunitinib Malate (SU11248) Promising for Metastatic Renal Cell Carcinoma (11/17/2005)
Two phase II multi-center clinical trials have demonstrated significant activity with the multi-targeted tyrosine kinase inhibitor SU11248 in patients with recurrent, metastatic renal cell carcinoma.
Addition of Iressa® To Tarceva/Avastin Does Not Improve Outcomes in Renal Cell Carcinoma (11/15/2005)
Researchers from Sarah Cannon Research Institute have reported that the addition of Iressa® (gefinitib) to Tarceva® (erlotinib) and Avastin® (bevacizumab) does not improve outcomes of patients with metastatic renal cell carcinoma (RCC) compared to Tarceva/Avastin.
Updated Results of Tarceva™/Avastin® in Renal Cell Carcinoma (RCC) (11/15/2005)
Researchers from the Sarah Cannon research Institute have reported updated results of a trial of Tarceva (erlotinib) plus Avastin (bevacizumab) in patients with metastatic clear-cell renal carcinoma.
Effectiveness of Reduced-Intensity Allogeneic Stem Cell Transplants for Renal Cell Carcinoma (10/24/2005)
Researchers affiliated with the European Bone Marrow Transplantation Solid Tumor Working Party have reported prognostic factors for survival of patients receiving reduced-intensity allogeneic stem cell transplants for renal cell carcinoma.
Avastin® Plus Tarceva® Provides Impressive Survival in Metastatic Renal Cell Carcinoma (10/12/2005)
Researchers from the Sarah Cannon research Institute have reported that Tarceva (erlotinib) plus Avastin (bevacizumab) produced a 25% objective response rate in patients with metastatic clear-cell renal carcinoma.
Retinoic Acid Modestly Improves Survival of Metastatic Renal Cell Cancer Treated with Interferon (6/24/2005)
Researchers affiliated with the European Organization for Research and Treatment of Cancer (EORTC) have reported that the addition of 13-cis-retinoic acid to interferon alfa-2a improves median survival by 4 months compared to interferon alone.
Sorafenib Improves Progression-Free Survival in Metastatic Renal Cell Carcinoma (5/16/2005)
Researchers from France reported at the 2005 annual meeting of the American Society of Clinical Oncology (ASCO) that treatment with the biologic agent sorafenib (BAY 43-9006) significantly improves progression-free survival with low toxicity in patients with metastatic renal cell carcinoma.
Nephrectomy in Patients with Metastatic Renal Cancer Improves Survival (3/31/2004)
Researchers from the Southwest Oncology Group (SWOG) and the European Organization for the Research and Treatment of Cancer Genitourinary Group have reported the results of two studies combined which indicate that nephrectomy decreases the risk of death by 31% in patients with metastatic renal cancer. The results of these analyses appeared in the March 2004 issue of
The Journal of Urology.
1
Thalidomide May Enhance Activity of Interleukin-2 in Renal Cell Cancer (3/30/2004)
Researchers from Israel have reported that the administration of thalidomide may improve the response to Interleukin-2 (IL-2) in patients with renal cell cancer after initial failure of IL-2. They attributed this effect to a decrease in IL-6 and C-reactive protein by thalidomide. The details of this study were reported in an advanced publication in the
International Journal of Cancer.
1
Adjuvant Vaccine Found Effective for Renal Cell Carcinoma (2/23/2004)
Researchers from Germany have reported successful prevention of relapses from early stage renal cell carcinoma with an adjuvant post-surgery autologous vaccine. The reports of this large randomized trial appeared in the February 21, 2004 issue of
The Lancet.
Bevacizumab (Avastin™) Has Activity in Clear Cell Type Renal Cancer (8/5/2003)
Researchers affiliated with the Eastern Cooperative Oncology Group (ECOG) reported that Avastin™ can delay the time to disease progression in patients with renal cell cancer of the clear cell type. The results of this randomized trial were published in the July 31, 2003 issue of the
New England Journal of Medicine.
Adjuvant Interferon-Alfa Not Effective for Locally Extensive Renal Cell Carcinoma (3/31/2003)
Researchers affiliated with the Eastern Cooperative Oncology Group have reported in the April 1, 2003 issue of the
Journal of Clinical Oncology that adjuvant INF-alfa did not prevent recurrences of renal cell cancer.
Cellular Immunotherapy Effective for Renal Cell Cancer (3/18/2003)
In the March 1, 2003 issue of the
Journal of Clinical Oncology, researchers from the National Cancer Institute reported that treatment of patients with advanced renal cell cancer with autologous tumor vaccine resulted in durable tumor responses.
Chemotherapy, Immunotherapy and Surgery Effective For Metastatic Renal Cell Cancer (10/10/2002)
Metastatic renal cell cancer is usually a fatal disease, however approximately 10% of patients appear to be cured by chemoimmunotherapy. Various chemotherapeutic agents have been added to the basic regimen of interleukin-2 (IL2) and interferon alfa (INF) but it is unclear whether or not one regimen is superior to another. Although there have been many attempts to improve the outcomes of patients with renal cell cancer, there has been relatively little progress in the past decade. However, some patients have complete remissions following an allogeneic transplant following a non-myeloablative chemoimmunosuppressive regimen and some patients appear to benefit from incomplete removal of the primary cancer. Researchers from Israel have reported that the complete response rate to chemoimmunotherapy can be improved after surgery. They reported their results in the October 2002 issue of
Cancer.
Gemzar® May Have Activity in Renal Cell Cancer (8/22/2002)
Patients with metastatic renal cell cancer have a poor prognosis with currently available treatments. For over a decade, metastatic renal cell cancer has been treated primarily with IL-2 (
Proleukin®) and alfa interferon. With this treatment, 10-15% of patients will have a complete or partial response and responding patients usually receive long-term, low-dose maintenance immunotherapy. The most active chemotherapy agents are Velban® and floxuridine, which can produce partial responses in 10% of cases. The addition of chemotherapy to a regimen of Proleukin® and alfa interferon has not produced consistent added benefits. In the September 2002 issue of the
Journal of Urology, Italian researchers present the results of a phase II trial suggesting that the addition of
Gemzar® to Proleukin® and alfa interferon may improve the outcomes of patients with metastatic renal cell cancer.
Gene Profiling Predicts Recurrences in Children with Wilms’ Tumor with Favorable Histology (8/6/2002)
Wilms' tumor is a relatively common childhood cancer. Approximately 90-95% of children with Wilm’s tumor have a favorable histology and a relatively good outcome with current treatments, even when metastatic. However, some children have recurrent disease despite having a favorable histology and researchers have been investigating ways to detect those who will be cured and those who will recur. This would allow for early intensive treatment of those destined to recur and less toxic treatment for those children who are easy to cure with moderate therapy. Researchers in England have investigated a new gene-expression profiling method that targets individual chromosomes. They used a technique called comparative expressed sequence hybridisation (CESH). The results of testing 18 children with Wilms’ tumor were published in the August 3, 2002 issue of the journal
The Lancet.
Anti-CD3 Activated, Vaccine-primed Lymphocytes Produce Durable Responses in Patients with Metastatic Renal Cell Cancer (6/5/2002)
According to results presented at the 38th Annual Meeting of the American Society of Clinical Oncology, researchers have successfully used adoptive immunotherapy to treat patients with stage IV renal cell cancer.
Mortality from Major Cancer Surgery and Morbidity From Prostate Surgery Lower in High Volume Hospitals Than in Low Volume Hospitals (4/16/2002)
There were two reports in the April 11 issue of the
New England Journal of Medicine which strongly support the concept that patients facing major cancer surgery should select a high volume hospital near where they live.
Four Weeks of Anticoagulation Better Than One Week Following Cancer Surgery (4/5/2002)
Researchers from Sweden, Italy, England and Israel have reported in the March 28 issue of the
New England Journal of Medicine that prolonged anticoagulation versus one week of anticoagulation is better for patients undergoing abdominal cancer surgery.
Plasma Free Metanephrines Best Test for Excluding or Confirming Pheochromocytoma (4/3/2002)
A multicenter international study has determined that plasma free metanephrines provide the best test for excluding or confirming the diagnosis of pheochromocytoma. The data establishing this was published in the March 20 issue of the
Journal of the American Medical Association.
|
|
Patient Home
